Physician profile
Michael Edward Thase
NPI 1982670279
$395,709.50
in general payments reported to CMS, 2019-2025
26 companies · $71K in 2025
The $71K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86K · 2020: $23K · 2021: $38K · 2022: $39K · 2023: $75K · 2024: $65K · 2025: $71K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $79K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $55K · Travel and Lodging: $46K · Honoraria: $27K · Food and Beverage: $3,535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $79,156.82 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $55,396.00 |
| Travel and Lodging | $45,884.14 |
| Honoraria | $27,025.00 |
| Food and Beverage | $3,534.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| H. Lundbeck A S | $89,119.25 | 2019-2025 | Rexulti, Brintellix, Escitalopram |
| Otsuka Pharmaceutical Co., LTD. | $69,971.59 | 2021-2024 | Rexulti |
| Boehringer Ingelheim International Gmbh | $26,748.88 | 2022-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23,227.03 | 2019-2024 | Rexulti |
| Janssen Research & Development, LLC | $22,438.88 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $22,029.44 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $21,390.18 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21,289.77 | 2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15,052.21 | 2023-2025 | Caplyta |
| Janssen Scientific Affairs, LLC | $13,614.45 | 2021-2024 | |
| Sage Therapeutics, LLC | $11,836.58 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $11,275.00 | 2024-2025 | |
| Mylan INC. | $10,405.00 | 2022-2023 | |
| Alkermes, INC. | $7,654.94 | 2019 | |
| Jazz Pharmaceuticals INC. | $6,458.82 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $4,712.50 | 2024-2025 | |
| Pfizer International LLC | $4,533.00 | 2020 | |
| Abbvie INC. | $3,714.16 | 2025 | |
| Luye Pharma (USA) LTD. | $3,654.98 | 2023 | Rykindo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,529.06 | 2023-2025 | |
| Janssen Global Services, LLC | $2,500.00 | 2020 | |
| Allergan, INC. | $1,455.00 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $43.63 | 2022 | |
| Upjohn US 1 LLC | $34.41 | 2019 | |
| Axsome Therapeutics, INC. | $20.74 | 2023 | Auvelity |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Thase listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.